Stockwinners Market Radar for December 08, 2017 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
BAND | Hot Stocks17:30 EDT Capital Research Global reports 12.6% passive stake in Bandwidth
|
IART | Hot Stocks17:30 EDT Capital Research Global reports 11.1% passive stake in Integra LifeSciences
|
AKTX... | Hot Stocks17:20 EDT On The Fly: After Hours Movers - HIGHER: Akari Therapeutics (AKTX), up 14.3% after it said that its Coversin Phase II trial met its primary endpoint... UTStarcom (UTSI), up 7.6% after the Tonghao Group reported a 9.9% stake in the company... Fate Therapeutics (FATE), up 6.7% after it treated its first patient in the APOLLO study of Fate-NK100... Overstock.com (OSTK), up 3.8% after Morgan Stanley (MS) reported an 11.4% passive stake in the company. LOWER: Cytokinetics (CYTK), down 5% after it said its VITALITY-ALS trial did not meet its primary endpoint.
|
UTSI | Hot Stocks17:15 EDT Tonghao reports 9.9% stake in UTStarcom, wants to become biggest holder - Tonghao Group said in a regulatory filing that it purchased the shares of UTStarcom with a view towards acquiring additional ordinary shares and becoming the largest shareholder of th company.
|
LLY | Hot Stocks17:01 EDT Eli Lilly: RAINFALL study met primary endpiont, but did not improve OS - Eli Lilly and Company announced top-line results from its Phase 3 RAINFALL study of CYRAMZA in combination with cisplatin and capecitabine or 5-FU in the first-line treatment of patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma. The trial met its primary endpoint of progression-free survival but did not improve overall survival, a secondary endpoint. The results will be submitted for presentation at a future medical meeting. The safety profile observed in the RAINFALL study was consistent with what has been previously observed for ramucirumab. Grade greater than or equal to3 adverse events occurring at a rate of five percent or greater and that were higher on the ramucirumab-plus-cisplatin-and-capecitabine/5-FU arm compared to the placebo-plus-cisplatin-and-capecitabine/5-FU arm were hypertension, hand-foot syndrome, and fatigue. "While we hoped that the positive PFS outcome would have translated into an OS benefit, these RAINFALL results highlight the challenges associated with improving outcomes for people with advanced gastric cancer," said Levi Garraway, M.D., Ph.D., senior vice president, global development and medical affairs, Lilly Oncology. "This is underscored by the fact that there have been no major advances over standard chemotherapy in the first-line HER2-negative gastric cancer treatment setting in the last decade."
|
CBB HCOM | Hot Stocks16:59 EDT Cincinnati Bell-Hawaiian Telcom merger receives Hawai'i DCCA approval - The Hawai'i Department of Commerce and Consumer Affairs' Cable Television Division announced the conditional approval of the transfer of control of Hawaiian Telcom's cable franchise to Cincinnati Bell Inc. (CBB). This development is an important step in the process of satisfying the closing conditions of Cincinnati Bell's combination with Hawaiian Telcom Holdco (HCOM). Leigh Fox, President and Chief Executive Officer of Cincinnati Bell, said, "We are pleased that our merger approval process is moving forward expeditiously and thank the DCCA for their leadership. The DCCA's approval is a significant step forward in the combination of Cincinnati Bell and Hawaiian Telcom, a merger that will accelerate our overarching strategy to create a diversified and balanced revenue mix by expanding our high-speed, high-bandwidth fiber optic network while building a complementary IT solutions and cloud services business in Cincinnati and Hawai'i."
|
GLBR | Hot Stocks16:45 EDT Global Brokerage trading resumes
|
MS OSTK | Hot Stocks16:41 EDT Morgan Stanley reports 11.4% passive stake in Overstock.com
|
APLS | Hot Stocks16:41 EDT Apellis provides update on PHAROAH trial of APL-2 for PNH - Apellis Pharmaceuticals presented an update on its Phase 1b PHAROAH trial at the 12th Annual Scientific Assembly of the International PNH Interest Group. The PHAROAH trial evaluates treatment with APL-2 in combination with eculizumab in patients with paroxysmal nocturnal hemoglobinuria, or PNH who have low hemoglobin levels despite treatment with eculizumab. Six patients were enrolled in the PHAROAH trial and two discontinued due to reasons unrelated to therapy. Four patients continue to be treated with daily doses of APL-2 270mg in combination with eculizumab for at least 12 months. Their average baseline hemoglobin level was 8.9 g/dL and the average number of transfusions in the 12 months preceding initiation of treatment was 5.25. Three of four patients were being treated with eculizumab at doses or frequencies in excess of 900mg/bi-weekly, while the remaining patient was being treated with 900mg/bi-weekly. The four patients had an average baseline reticulocyte count of 332 103 microL and average lactate dehydrogenase levels of 210 U/L. All four patients remain transfusion independent with an average hemoglobin level of 11.6 g/dL at one year of treatment. Average reticulocyte count decreased to 56.02 103 microL by month one and has remained steady since that time. Average LDH level was 184.5 U/L at one year of treatment. The three patients co-treated with high dose eculizumab have had their dose lowered to 900 mg bi-weekly during the course of the study, with no impact on hemoglobin, LDH or reticulocytes.
|
NLSN | Hot Stocks16:36 EDT Cumulus Media signs long-term extension for radio measurement with Nielsen - Nielsen announced that Cumulus Media has signed a multi-year extension for radio ratings services for all Portable People Meter and radio diary measured markets. Westwood One, the largest radio network in the U.S. and the national-facing arm of Cumulus Media, is also included in this agreement. This multi-year agreement provides Nielsen's radio and network radio ratings services for Cumulus and Westwood One's 446 radio stations across 90 local markets. In addition to extending Nielsen's core audio ratings services, Cumulus and Westwood One will continue to have access to local qualitative behavioral data from Nielsen Scarborough, enhanced talent analytics from Nielsen N-Score and national networks ratings from Nielsen RADAR. As part of the agreement, Westwood One will extend its use of Nielsen Marketing Cloud and Pointlogic for enhanced purchase-based marketing and media planning functions.
|
PETQ | Hot Stocks16:35 EDT Park West Asset Management reports 5.5% passive stake in PetIQ
|
AKTX | Hot Stocks16:35 EDT Akari Therapeutics trading resumes
|
AGLE | Hot Stocks16:31 EDT Nantahala Capital reports 10.9% passive stake in Aeglea BioTherapeutics
|
M | Hot Stocks16:31 EDT Macy's executive chairman Terry Lundgren to retire - Macy's announced that executive chairman Terry Lundgren will retire from the board of directors effective Jan. 31, 2018. The board has appointed Jeff Gennette, who has been CEO since March 2017, to the additional role of chairman effective Jan. 31, 2018. This will complete the planned transition that was announced in June 2016. Marna Whittington remains Lead Independent Director. Following Lundgren's retirement, the board will have 10 directors. "I am proud of our company's growth, accomplishments and the talent we developed during the 14 years I have led Macy's, Inc.," Lundgren said. "I have worked closely with Jeff and his team over the past two years, focusing on the changes and vision required for future success. I am confident that the company has the strategies, resources, talent and leadership to capitalize on the fundamental shifts in consumer shopping patterns we have all experienced. I continue to be impressed with Jeff's leadership, his decisiveness and his engagement with all levels of our outstanding organization. I would also like to thank the 140,000 employees of Macy's, Bloomingdale's and Bluemercury who make up the most talented retail workforce in America! It has been an honor to work with you."
|
M | Hot Stocks16:30 EDT Macy's executive chairman Terry Lundgren to retire
|
BEBE | Hot Stocks16:30 EDT Bebe Stores trading resumes
|
PEP | Hot Stocks16:27 EDT PepsiCo to move stock exchange listing to Nasdaq - PepsiCo announced it will be transferring its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market effective December 19, 2017 after market close. PepsiCo shares are expected to begin trading as a Nasdaq-listed security on December 20, 2017, with the common stock continuing to trade under the symbol "PEP."
|
GLBR | Hot Stocks16:22 EDT Global Brokerage to delist shares from NASDAQ Capital Market - Global Brokerage announced that it has notified The NASDAQ Stock Market of its intention to voluntarily withdraw its Class A common stock, par value 1c , from listing on The NASDAQ Capital Market. Global Brokerage intends to file a Form 25, notification of removal from listing under Section 12 of the Securities Exchange Act of 1934, with the SEC on or about December 19, notifying the SEC of its delisting from the exchange. The last day of trading on the exchange will be December 28. Global Brokerage has not arranged for listing or registration of its common stock on another national securities exchange. Global Brokerage's board intends to withdraw its common stock from listing on the exchange as a result of several factors, including the intention to deregister its common stock under the Securities Exchange Act of 1934, as amended, and terminate its duty to file periodic reports with the SEC in order to reduce its costs of compliance with the rules of the SEC and of the exchange.
|
CYTK | Hot Stocks16:21 EDT Cytokinetics: VITALITY-ALS trial did not meet primary endpoint - Cytokinetics announced the presentation of results from VITALITY-ALS, the international Phase 3 clinical trial of tirasemtiv in patients with amyotrophic lateral sclerosis, at the 28th International Symposium on ALS and Motor Neurone Disease in Boston. This presentation follows a prior announcement that the trial did not meet the primary endpoint of change from baseline in slow vital capacity which was evaluated at 24 weeks following randomization or any of the secondary endpoints in the trial which were evaluated at 48 weeks. The results were presented by Jeremy Shefner, M.D., Ph.D., Lead Investigator of VITALITY-ALS, Professor and Chair of Neurology at Barrow Neurological Institute, and Professor and Executive Chair of Neurology at University of Arizona, Phoenix. "Although we are profoundly disappointed with these results, we believe that data from VITALITY-ALS provide validation for the mechanism of action of fast skeletal muscle troponin activation. The effects of tirasemtiv observed in patients with ALS support the future development of CK-2127107, our next-generation fast skeletal muscle troponin activator which is the subject of FORTITUDE-ALS, our ongoing Phase 2 clinical trial in patients with ALS," said Robert I. Blum, Cytokinetics' President and CEO. "As recently published Phase 1 studies demonstrate, CK-2127107 may be more effective and better tolerated than tirasemtiv. We are humbled by the outpouring of support we have received from the ALS community and will continue our search for a potential therapy to slow the progressive respiratory decline and muscle weakness which characterize this dreadful disease."
|
ERIE | Hot Stocks16:16 EDT Erie Indemnity raises quarterly Class A dividend 7.3% to 84c per share - Erie Indemnity's board has agreed to increase the regular quarterly cash dividend from 78.25c to 84c on each Class A share and from $117.375 to $126.00 on each Class B share. This represents a 7.3% increase in the payout per share over the current dividend rate. The next quarterly dividend is payable Jan. 23, 2018, to shareholders of record as of Jan. 8, 2018, with a dividend ex-date of Jan. 5, 2018. Erie Indemnity Company has paid regular shareholder dividends since 1933.
|
MORN | Hot Stocks16:10 EDT Morningstar increases dividend 8.7%, authorizes $500M share repurchase plan - The board of Morningstar declared a quarterly dividend of 25c per share. The dividend is payable Jan. 31, 2018, to shareholders of record as of Jan. 5, 2018. The declaration reflects an 8.7% increase in the quarterly dividend to 25c per share from 23c. Morningstar's board also approved a new share repurchase program that authorizes the company to repurchase up to $500M in shares of the company's outstanding common stock, effective Jan. 1, 2018. The existing program expires on Dec. 31. The share repurchase authorization permits the company to repurchase shares from time to time at prevailing market prices on the open market or in private transactions in amounts that management deems appropriate.
|
GLBR | Hot Stocks16:10 EDT Global Brokerage trading halted, news pending
|
QGEN | Hot Stocks16:08 EDT Qiagen to transfer U.S. listing of global shares to NYSE from NASDAQ - Qiagen announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange from the NASDAQ Global Market.
|
AKTX | Hot Stocks16:07 EDT Akari says Coversin Phase II trial met primary endpoint - Akari Therapeutics announced that the three additional patients that were enrolled into the Phase II COBALT trial of Coversin in paroxysmal nocturnal hemoglobinuria, considered together with the earlier five patients, met the primary endpoint. The primary endpoint in this clinical trial is reduction in serum LDH to less than or equal to1.8 times the upper limit of normal for the investigator's reference laboratory to day 28. The last three patients enrolled into the Phase II trial utilized a revised dosing regimen which included changing the initial dose of 30 mg every 24 hours to a dose of 45 mg every 24 hours. The 45 mg dosing regimen is the intended dose for the Phase III PNH trials of Coversin discussed with the U.S. Food and Drug Administration at a Type B End of Phase II Meeting in September 2017. "We are encouraged by the results from the Phase II trial, especially the lower mean LDH value observed in the last three patients enrolled into the trial treated with 45 mg daily compared to the patients treated with 30 mg daily," commented Dr. David Solomon, Chief Executive Officer of Akari Therapeutics. "We are on track to progress into Phase III clinical trials in the first quarter of 2018 with the revised dosing regimen of 45 mg, as discussed with the FDA."
|
FATE | Hot Stocks16:05 EDT Fate Therapeutics treats first patient in APOLLO study of Fate-NK100 - Fate Therapeutics announced that the first subject has been treated in the APOLLO study of Fate-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based treatment. The clinical trial is intended to evaluate the safety and determine the maximum dose of Fate-NK100, the company's first-in-class, donor-derived adaptive memory natural killer, or NK, cell cancer therapy, as a monotherapy when administered intraperitoneally in the outpatient setting. A clinical assessment of patients with ovarian cancer has previously shown that endogenous NK cells within the peritoneal fluid exhibit an altered phenotype with reduced cytolytic function. The APOLLO study is an open-label, accelerated dose-escalation, Phase 1 clinical trial in subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer. Up to three dose levels of Fate-NK100 are intended to be assessed to evaluate safety and determine the maximum dose. Other endpoints to be evaluated include objective response rate at 28 days, and progression-free and overall survival at six months. Subjects with stable disease or better at Day 28 following infusion may be considered for retreatment.
|
PSEC | Hot Stocks16:03 EDT Prospect Capital CEO acquires 110,000 common shares - In a regulatory filing, Prospect Capital CEO John F. Barry disclosed the acquisition of 110,000 common shares of the company at a price of $6.6988 per share.
|
PERY | Hot Stocks16:02 EDT George Feldenkreis reports 11.3% stake in Perry Ellis
|
CPRX | Hot Stocks16:01 EDT Great Point Partners reports 5.14% passive stake in Catalyst Pharmaceuticals
|
BEBE | Hot Stocks16:01 EDT bebe stores to voluntarily delist from NASDAQ, to start trading on OTCQB - bebe stores announced that it has notified the NASDAQ Stock Market on December 8, 2017 of its intention to voluntarily delist its common stock from the NASDAQ Capital Market. The company intends to cease trading on the NASDAQ Stock Market on Monday, December 18, 2017. Therefore the last day of trading on the Nasdaq Stock Market will be Friday, December 15, 2017. Once delisted, the company anticipates its stock will begin trading on the OTCQB Market, which is operated by OTC Markets Group, a centralized electronic quotation service for over-the-counter securities, on Monday, December 18, 2017. The decision of the company's board of directors to move the listing of its common stock from Nasdaq to the OTCQB was driven by cost savings. The company intends to retain the trading symbol BEBE.
|
AKTX | Hot Stocks16:00 EDT Akari Therapeutics trading halted, news pending
|
PFNX | Hot Stocks16:00 EDT Sanders Morris Harris reports 5% stake in Pfenex
|
BEBE | Hot Stocks16:00 EDT Bebe Stores trading halted, news dissemination
|
SFIX | Hot Stocks15:59 EDT Miller Value Partners reports 13.43% passive stake in Stitch Fix
|
RESI | Hot Stocks15:45 EDT Brown Advisory reports 5.43% passive stake in Altisource Residential
|
IBKC | Hot Stocks15:27 EDT Iberiabank pays $11.69M to settle False Claims Act violations - The Justice Department announced today Iberiabank agreed to pay the United States $11,692,149 to resolve allegations that they violated the False Claims Act by falsely certifying they were complying with Federal requirements in order to obtain insurance on mortgage loans from the Federal Housing Administration. Reference Link
|
BTC... | Hot Stocks15:13 EDT The Intersection: Crypto and Wall Street This Week - As bitcoin, ethereum and other cryptocurrencies get increasing attention from investors, Wall Street and its traditional banks continue to adjust to the shift. Catch up on this week's top stories highlighting the intersection of these old guard and new school areas of finance with this recap compiled by The Fly: 1. SURGE IN PRICE, MAINSTREAM ATTENTION: Bitcoin's price in U.S. dollars, which had only topped $10,000 for the first time last week, rocketed past $19,000 on one of its major exchanges on Thursday. The wild trading on Wednesday and Thursday of this week brought with it an associated spike in mainstream attention from CNBC and others media outlets. 2. CBOE FUTURES LAUNCH SUNDAY: As previously announced on December 4, CBOE's (CBOE) Futures Exchange plans to offer trading in bitcoin futures beginning at 5:00 p.m. CT on Sunday, December 10, 2017, at the start of Global Trading Hours. Monday, December 11, will be the first full day of trading, and trading will be free through December. CBOE's bitcoin futures will trade on CFE under the ticker symbol 'XBT.' XBTSM futures are cash-settled contracts based on Gemini's auction price for bitcoin, denominated in U.S. dollars. 3. BANKS HESITANT: Bank of America (BAC) and Citigroup (C) won't offer clients access to the first bitcoin futures market when it goes live on Sunday, while Goldman Sachs (GS) will only offer access to certain customers at the start, people familiar with the matters told The Wall Street Journal. Morgan Stanley (MS) is still evaluating its approach to bitcoin futures, the report added. A CBOE spokeswoman said its planned launch of the futures this Sunday will go ahead as planned, but declined to release a list of banks prepared to handle trading in the bitcoin futures, The Journal noted. 4. DISCOUNT BROKERS MAY GET INVOLVED: Morgan Stanley analyst Michael Cyprys told investors in a note published this week that he expects discount brokers including E-Trade (ETFC), TD Ameritrade (AMTD) and Ally Financial (ALLY) to offer bitcoin futures trading within the next few months. Among them, he views TD Ameritrade as most likely to embrace bitcoin and lead the way and Charles Schwab (SCHW) as likely to be a latecomer. Cyprys added that he was surprised, given its status as a "challenger brand," that E-Trade has said it will take "a wait-and-see" approach. 5. TARGET RAISED TO KEEP PACE: On Thursday, Standpoint Research analyst Ronnie Moas raised his 2018 price target for bitcoin to $28,000 from $20,000. Just over a week ago the analyst raised his 2018 target to $20,000 from $14,000. Moas pointed out that his longer term public target remains $50,000. Noting that the supply of bitcoin is capped, Moas contends, "We are a couple of years away from being in a situation where hundreds of millions of people around the world are trying to get their hands on a few million bitcoin." 6. CITRON GOES BACK TO SHORTING BITCOIN TRUST: Citron Research, the short-selling focused firm run by Andrew Left, tweeted on Thursday: "Bitfinex, the largest Bitcoin exch has threatened legal action against critics. Could be the Lehman moment of Bitcoin....Citron has agreed to cover legal fees for bloggers expressing opinions. We have been in contact. Open dialogue in markets is important...That being said the $GBTC premium has evaporated and now we cautiously entered a new short position at $1800 on GBTC." 7. BITCOIN STOCK PLAYS: Cryptocurrency revenues have been pointed to as reasons to be bullish on Advanced Micro Devices (AMD) and Nvidia (NVDA) in select research. Overstock (OSTK), which has invested in blockchain technology and has a unit planning a launch of its own cryptocurrency, is another stock that has been touted as a way to play the crypto theme. PRICE ACTION: As of time of writing, bitcoin rose about 42% this week to $15,344 in U.S. dollars according to CoinDesk. Meanwhile, AMD shares fell 7% this week to $9.95 and Nvidia dropped 3% on a weekly basis to $191.54. Bitcoin Investment Trust rose about 3% this week to $1,675. WANT BITCOIN NEWS ALERTS?: To receive alerts on stories relating to bitcoin and other cryptocurrencies, Fly subscribers can enter "Bitcoin" into the "Add symbols" box of their portfolios.
|
BID | Hot Stocks15:01 EDT Sotheby's says contemporary art in France sales up 41% in 2017 - Sotheby's announced that December sales of Contemporary Art in Paris concluded yesterday with a total of $51.1M, bringing the annual total for the category in France to $88.7 million, a 41% increase compared to 2016.
|
CHUBA | Hot Stocks15:00 EDT Neuberger Berman reports 10.454% passive stake in CommerceHub
|
AMZN | Hot Stocks14:43 EDT Former Amazon analyst heading to prison for insider trading - A former financial analyst at Amazon.com was sentenced in U.S. District Court in Seattle to 6 months in prison for securities fraud involving insider trading. Brett Kennedy pleaded guilty in September, admitting that in April 2015, he provided non-public quarterly financial results to a friend who then purchased Amazon stock and sold it at a profit once the results were made public. The friend paid Kennedy, who is no longer employed at Amazon, for the inside information. Reference Link
|
HON | Hot Stocks13:55 EDT Honeywell authorizes $8B common stock repurchase - In a regulatory filing, Honeywell International announced that its board authorized the company to repurchase up to $8B of its common stock, including approximately $1.5B of remaining availability under its previously announced $5B share repurchase authorization. The company presently expects to repurchase outstanding shares from time to time to generally offset the dilutive impact of employee stock based compensation plans.
|
TRIL | Hot Stocks13:55 EDT Matrix Capital reports 16.5% passive stake in Trillium Therapeutics
|
BAND | Hot Stocks13:52 EDT Alta Park Capital reports 5.95% passive stake in Bandwidth
|
SKYW UAL | Hot Stocks13:49 EDT SkyWest up 2% after Bloomberg says United weighing ExpressJet stake
|
VIAB... | Hot Stocks13:43 EDT Box Office Battle: 'Coco' again expected to win the weekend - With no new major releases this weekend, Disney's (DIS) Pixar animated film "Coco" is expected to remain in first place, with an estimated domestic gross of about $18M in its third weekend at theaters. Vying for second place and each expected to earn around $9M are Time Warner's (TWX) Warner Bros' super hero film "Justice League" and Lionsgate's (LGF.A, LGF.B) drama "Wonder." Opening this weekend and expected to earn $5M is Broad Green Pictures action-comedy "Just Getting Started," which is opening at 2,146 locations and stars Morgan Freeman, Tommy Lee Jones, and Rene Russo. This will be Broad Green's last film, as Broad Green announced in August that it was closing down production after three years. Next weekend, Disney's "Star Wars: The Last Jedi" is opening and expected to dominate theaters. Other publicly traded companies in filmmaking include 21st Century Fox (FOX, FOXA), Comcast (CMCSA, CMCSK), Sony (SNE), and Viacom (VIA, VIAB).
|
SAGE | Hot Stocks13:28 EDT Sage Therapeutics CEO says SAGE-217 patents go out to 2034 - Jeff Jonas is speaking on CNBC.
|
BID | Hot Stocks13:24 EDT Sotheby's says 'A Life of Luxury' sales series concluded with $117.3M - Sotheby's said its "A Life of Luxury" sales series concluded yesterday in New York with 1,640 lots of jewelry, watches, cars, wine and fashion achieving $117.3M across six auctions.
|
BHGE | Hot Stocks13:03 EDT Baker Hughes reports U.S. rig count up 2 to 931 rigs - Baker Hughes reports that the U.S. rig count is up 2 rigs from last week to 931, with oil rigs up 2 to 751, gas rigs unchanged at 180, and miscellaneous rigs unchanged. The U.S. Rig Count is up 307 rigs from last year's count of 624, with oil rigs up 253, gas rigs up 55, and miscellaneous rigs down 1 to 1. The U.S. Offshore Rig Count is unchanged from last week at 20 and down 2 rigs year-over-year. The Canada Rig Count is down 3 rigs from last week to 219, with oil rigs up 1 to 112 and gas rigs down 4 to 107. The Canada Rig Count is down 11 rigs from last year's count of 230, with oil rigs down 5, gas rigs down 5, and miscellaneous rigs down 1 to 1.
|
BUR | Hot Stocks12:49 EDT Burcon announces board change, confirms no material undisclosed information - Burcon NutraScience announced that effective today, Matthew Hall has resigned as a director of the corporation. As previously announced on September 8, 2017, Hall received more votes withheld than votes in favor of his election as a director at the corporation's annual and special meeting held on September 7, 2017. In accordance with the corporation's majority voting policy, Hall was required to submit his resignation to the board of directors for its consideration. After due consideration, the Board decided to accept his resignation. At the request of IIROC on behalf of the Toronto Stock Exchange, Burcon also confirms that it is not aware of any material undisclosed information relating to the Corporation that may be contributing to the recent increase in market price and level of trading activity of its shares.
|
PSX | Hot Stocks12:35 EDT Phillips 66 announces 2018 capital budget of $2.3B - Phillips 66 announced its 2018 capital budget of $2.3B, which includes $1.4B of growth capital and $900M of sustaining capital. In Midstream, Phillips 66 plans to invest $1.2B, including $1B of growth capital, in its Natural Gas Liquids and Transportation businesses. The company is developing growth projects integrated with its existing assets and infrastructure, such as ongoing expansion of the Beaumont Terminal, additional Gulf Coast fractionation capacity, and investment in pipelines and other terminals. Midstream capital includes budgeted spending of $595M by Phillips 66 Partners, with $85M directed toward maintenance. Growth capital at the partnership will support organic projects, such as the Sand Hills Pipeline expansion, completion of the Bayou Bridge Pipeline eastern segment, and an isomerization unit at the Phillips 66 Lake Charles Refinery. Phillips 66 plans $827M of capital spending in Refining, with $541M for reliability, safety and environmental projects. Refining growth capital of $286M is for small, high-return, quick payout projects primarily to increase clean product yields. Projects include completion of the fluid catalytic cracking unit modernization at the Bayway Refinery and FCC optimization at the Sweeny Refinery.
|
DPW | Hot Stocks12:20 EDT Digital Power trading resumes
|
NVLN | Hot Stocks11:31 EDT EdgePoint Investment reports 10.6% passive stake in Novelion Therapeutics
|
SCMP | Hot Stocks11:27 EDT Linden Capital takes 5.1% passive stake in Sucampo - Linden Capital reports a 5.1% stake in Sucampo Pharmaceuticals, which represents over 2.48M shares. The filing does not allow for activism.
|
SHPG | Hot Stocks11:24 EDT Shire says John Miller will be named Interim CFO - Shire announced on August 21 that Jeff Poulton, Chief Financial Officer, would leave the company at the end of the year. On November 20, Shire announced that Thomas Dittrich will join the company as CFO in early 2018. Shire today announces that Jeff Poulton will leave on December 31, 2017, and John Miller, Shire's Senior Vice President of Finance, will be appointed Interim Chief Financial Officer with effect from January 1, 2018, until Dittrich commences his employment with Shire.
|
FLS | Hot Stocks11:16 EDT EdgePoint Investment reports 10.4% passive stake in Flowserve
|
BANC | Hot Stocks11:16 EDT Banc of California drops after Muddy Waters tweets about accounting fraud - Muddy Waters Research just tweeted, "Reminiscent of Crazy Eddie taking auditors to strip clubs (back when auditors were almost all men) cc: @SamAntar & heard a certain Brazilian cult-of-personality group of companies used to show visiting analysts from the U.S. an amazing time. (The group blew up of course.)" Muddy Waters was replying to a tweet that read, "$BANC engaged in accounting fraud while taking sell side analysts to strip clubs, according to new whistleblower suit." Shares of Banc of California are down 4% to $20.95 in morning trading.
|
GGG | Hot Stocks11:12 EDT Graco announces 3-for-1 stock split, increases quarterly dividend by 10.4% - The Board of Directors of Graco Inc announced the following actions related to its common stock of which there are approximately 56 million shares outstanding: The declaration of a 3-for-1 split of the company's common stock, to be distributed on December 27, 2017, for shareholders of record as of December 18, 2017. This is the twelfth split of the company's common stock since it was first publicly offered in 1969. The declaration of a regular quarterly dividend of 39.75c per common share, or 13.25c per post-split share, an increase of 10.4%, payable on February 7, 2018, to shareholders of record at the close of business on January 22, 2018.
|
AOBC RGR | Hot Stocks11:10 EDT American Outdoor cuts guidance amid 'challenging market conditions' - Shares of American Outdoor Brands (AOBC) fell sharply in late morning trading after the parent of Smith & Wesson slashed its guidance for fiscal 2018, citing "challenging market conditions." EARNINGS AND GUIDANCE: After the market close on Thursday, American Outdoor Brands reported second quarter adjusted earnings per share of 11c, beating analysts' estimates of 7c, but well below the 68c the company reported in the year-ago quarter. Sales of $148.4M beat the $142.18M consensus, but dropped 36.4% from a year ago. American Outdoor previously forecast Q2 EPS of 7c-12c and revenue of $140M-$150M. Looking ahead, American Outdoor slashed its FY18 adjusted EPS view to 57c-67c from $1.04-$1.24 and its revenue view to $650M-$675M from $700M-$740M, significantly missing analysts' estimates of $1.10 and $712.64M, respectively. Third quarter adjusted EPS is currently forecast at 7c-10c on revenue of $170M-$180M, also well below the consensus of 41c and $209.38M, respectively. In a statement, president and CEO James Debney said that the company faced "difficult market conditions" in the quarter, adding that "Total revenue for the quarter faced a challenging comparison to last year, when we believe strong consumer demand was driven by personal safety concerns and pre-election fears of increased firearm legislation." Debney also noted that "Lower shipments in our firearms business reflected a significant reduction in wholesaler and retailer orders versus the prior year, and were partially offset by higher revenue in our Outdoor Products & Accessories business." For the second half of 2018, Debney said the company's focus remains on "ensuring that our internal manufacturing resources are aligned with demand." WHAT'S NOTABLE: For its most recent quarter, American Outdoor competitor Sturm Ruger (RGR) reported EPS and sales that fell well below the consensus, with the company commenting that "net sales decreased 35% and EPS decreased 50% from the third quarter of 2016. The decrease in earnings is attributable to the sales decline and the unfavorable de-leveraging of fixed manufacturing costs due to the decline in production volumes." ANALYST COMMENTARY: In a post-earnings note to clients, Wedbush analyst James Hardiman said the company's guidance reduction was a "first and important step." While the Street probably still won't believe the updated estimates until there is some evidence of bottoming, Hardiman, who maintained an Outperform rating and $19.50 price target, said he still views the stock as significantly undervalued compared to his lowered estimates. Craig-Hallum analyst Steven Dyer kept a Hold rating on the stock, but lowered his price target to $15 from $17, saying that it remains to be seen if normal buying will pick up when promotions ease. PRICE ACTION: In late morning trading, American Outdoor Brands has rebounded a bit, now down only 6.7% to $13.87, while Sturm Ruger is down 5% to $53.10.
|
TEVA | Hot Stocks10:52 EDT Teva may cut up to 10,000 jobs globally, Bloomberg reports - Teva Pharmaceutical is considering reducing its global workforce by up to 10,000 as new CEO Kare Schultz seeks to cut costs, Bloomberg reports, citing people with knowledge of the matter. Teva aims to reduce expenses by $1.5B-$2.0B, sources told Bloomberg. The stock in morning trading is up 5% to $15.69. Reference Link
|
WFC | Hot Stocks10:49 EDT President Trump says Wells Fargo fines will not be dropped - President Donald Trump tweeted, "Fines and penalties against Wells Fargo Bank for their bad acts against their customers and others will not be dropped, as has incorrectly been reported, but will be pursued and, if anything, substantially increased. I will cut Regs but make penalties severe when caught cheating!"
|
AKER | Hot Stocks10:34 EDT Akers Biosciences secures further IP protection for Akers Wellness line - Akers Biosciences announces that its Health and Wellness product line is now protected by ten patents in the US, the European Union, Japan, China and Hong Kong, with additional patents pending in the European Union and India; and six trademark registrations in the U.S. The patents address three novel areas of technology developed by Akers Bio for the company's Akers Wellnesss line. The first group of three patents expand the US protection already granted to further countries and cover the unique design of the disposable cartridge which contains the reagent for the detection of wellness markers in exhaled breath. The reagent contained within is analyzed using optical scanning technology after contact with the user's breath sample and produces a quantitative result through the Akers Wellness(TM) app on the user's smartphone or tablet. Included in the patent group are the unique form factor, optical lens and read elements and the unique 'U' shaped airflow pathway. A second group of three patents cover the Company's BreathScan Lync technology. BreathScan Lync is the new bluetooth-enabled reading device from Akers Wellness which enables users to track the results of Akers Wellness breath-based tests via their mobile device. A third group of four patents cover the device and apparatus used to determine levels of ketones in exhaled breath indicative of ketosis, an optimal fat-burning state for weight loss.
|
AMZN OKTA | Hot Stocks10:19 EDT Amazon's AWS announces single sign-on solution - AWS (AMZN) commented yesterday, "AWS Single Sign-On is a cloud SSO service that makes it easy to centrally manage SSO access to multiple AWS accounts and business applications. It enables users to sign in to a user portal with their existing corporate credentials and access all of their assigned accounts and applications from one place. With AWS SSO, you can easily manage SSO access and user permissions to all of your accounts in AWS Organizations centrally. Further, by using the AWS SSO application configuration wizard, you can create Security Assertion Markup Language 2.0 integrations and extend SSO access to any of your SAML-enabled applications. AWS SSO also includes built-in SAML integrations to many business applications, such as Salesforce, Box, and Office 365. With just a few clicks, you can enable a highly available SSO service without the upfront investment and on-going maintenance costs of operating your own SSO infrastructure. There is no additional cost to enable AWS SSO. It is now available in the US East Region." The Fly notes that Okta (OKTA), an enterprise-grade, identity management service, built for the cloud, is down 4.6% to $27.84.
|
SIGM... | Hot Stocks10:15 EDT Street Check: Benchmark predicted Sigma Designs could be bought by Silicon Labs - Shares of Sigma Designs (SIGM) jumped in morning trading after Silicon Laboratories (SLAB) agreed to acquire the company for about $282M. The deal comes after Sigma reported weaker than expected quarterly results, and several months after an analyst speculated about a potential deal. BACKGROUND: In a June 7 note, Benchmark analyst Gary Mobley speculated that Sigma Designs could be a "prime acquisition target" for Silicon Labs or MaxLinear (MXL) if it shed assets to become a pure play IoT chip/cloud infrastructure. Mobley said if Sigma was not acquired, but was able to raise $100M by selling non-core, non-IoT businesses, Sigma could make additional acquisitions to strengthen its IoT focus. ACQUISITION ANNOUNCEMENT: After the market close on Thursday, Silicon Labs announced that it will buy Sigma Designs for $282M, or $7.05 per share in a cash transaction. The deal, which is subject to certain closing conditions, is expected to close in the first calendar quarter of 2018. Key to the deal is Sigma's Z-Wave IoT technology for smart home solutions, and Silicon Labs CEO Tyson Tuttle commented that "By adding Z-Wave technology to Silicon Labs' connectivity portfolio, we will be better positioned to serve this fast-growing market." Silicon Labs intends to work in collaboration with the Z-Wave Alliance to drive adoption and development of Z-Wave technology, it said. In the event the closing conditions are not met, Sigma said it will sell its Z-Wave business to Silicon Labs for $240M. In addition, Sigma said it plans to divest or wind down its Smart TV business, and is in active discussions with prospective buyers to divest its Media Connectivity business. Separately, Sigma Designs reported a third quarter loss per share of (25c) on revenue of $33.9M, missing analysts' consensus estimates of (15c) and $38.55, respectively. WHAT'S NOTABLE: In July, Sigma Designs said it had engaged Deutsche Bank as a financial advisor to explore strategic alternatives, including continuing with its restructuring plans, selling or spinning off certain products or the sale of the company. In October, the company announced major restructuring activities to streamline the Connected Smart TV Platforms business and accelerate a return to profitability. As a result, Sigma said it planned to cut 200-250 jobs. REACTION: Weighing in on the acquisition announcement, Benchmark's Mobley downgraded Sigma Designs this morning to Hold from Buy, telling investors that the 26% takeover premium from Silicon Labs is a good deal for shareholders. Sigma shares were also downgraded to Hold from Buy at Craig-Hallum and Lake Street. Craig-Hallum's Richard Shannon called the deal a "disappointing outcome," as he thought the sum of the parts would be closer to $9 per share. He does not see a better price, as he thinks the deal was "well-shopped." Lake Street's Jaeson Schmidt said he is "not surprised" by the news following Sigma's exploration of strategic alternatives. He sees little risk to getting the deal done. PRICE ACTION: Sigma Designs is up nearly 23% in morning trading to $6.88, while Silicon Laboratories is up about 0.33% to $90.50. OTHERS TO WATCH: MaxLinear, a company that had been rumored to be a potential suitor for Sigma, is up 1.5% to $25.37.
|
KKR | Hot Stocks10:01 EDT KKR to acquire Hyperion from Sandvik, terms not disclosed - KKR announced it is acquiring Hyperion, a leading manufacturer of industrial tool components, from Sandvik. This transaction marks KKR's first acquisition of a middle-market business in the industrials sector and is being funded through KKR's Americas XII Fund. Headquartered in Fair Lawn, New Jersey with approximately 1,400 employees, Hyperion is a global provider of manufacturing products using cemented carbide, cubic boron nitride and synthetic diamond - high quality materials known for their hardness and toughness. This transaction, which is subject to regulatory approvals and other customary closing conditions, is expected to close during the first half of 2018.
|
HP | Hot Stocks09:51 EDT Helmerich & Payne announces acquisition of Magnetic Variation Services - Helmerich & Payne announced that it has acquired Magnetic Variation Services, a company involved in enhancing the accuracy of directional drilling and wellbore optimization. Founded in 2010, MagVAR will maintain its headquarters in Westminster, Colorado. The financial terms of the acquisition were not disclosed. However, in connection with the transaction and in part as consideration for MagVAR equity owned by certain of its management members, H&P granted certain management members restricted stock awards covering 213,904 shares of H&P common stock in the aggregate.
|
PSO... | Hot Stocks09:30 EDT Pearson names chairman of Snap, Michael Lynton, to board of directors - Pearson (PSO) announces the appointment of Michael Lynton as an independent non-executive director, effective from February 1st 2018. Michael was formerly chairman and CEO of Sony Entertainment (SNE), a role he held from 2012 to 2017. Prior to this he served as chairman and CEO of Sony Pictures Entertainment from 2002 to 2012. He is currently chairman of Snap Inc. (SNAP) having joined the company in 2017. He is also a non-executive director on the board of Ares Management, and was formerly a non-executive director at Samsonite and Modern Times Group. In a career spanning over 35 years, Michael has held senior leadership roles at Penguin Group, The Walt Disney Company (DIS) and Time Warner (TWX).
|
EROS | Hot Stocks09:21 EDT Eros, Metrological partner to bring films to OTT operators - Eros International announced that Eros Now, its cutting-edge digital over-the-top platform, has partnered with Metrological, a cloud-based TV app store and content distribution platform providing seamless integrated app and OTT experiences to MVPDs.
|
BAC... | Hot Stocks09:18 EDT On The Fly: Pre-market Movers - HIGHER: Bank of America (BAC), up 1% after First American (FAF) agreed to buy Bank of America's lien release business operations... Hologic (HOLX), up 3.2% after being upgraded to Conviction Buy from Buy at Goldman Sachs... Cloudera (CLDR), up 8.1% after reporting quarterly results. LOWER: Globalstar (GSAT), down 2.4% after its 38M share Spot Secondary priced at $1.20... Party City (PRTY), down 5.6% after its 10M share Spot Secondary priced at $12.90... American Outdoor Brands (AOBC), down 17% after reporting quarterly results... Tellurian (TELL), down 14.7% after its 10M share Spot Secondary priced at $10.00.
|
DPW | Hot Stocks09:15 EDT Digital Power trading halted, news pending
|
MFC | Hot Stocks09:02 EDT Manulife Financial announces chair transition and succession - Richard DeWolfe, Chair of the Board of Directors of Manulife Financial Corporation and The Manufacturers Life Insurance Company, announced on behalf of the Board the appointment of John Cassaday as Vice Chair, effective December 7. DeWolfe will retire from the Board in May 2018, having completed his term. Cassaday, as Vice Chair, will work with DeWolfe in managing a smooth transition of the affairs of the Board until the annual meeting on May 3, 2018, following which Cassaday will become Chair of the Board. Cassaday, who joined the Board in 1993, was previously President and Chief Executive Officer of Corus Entertainment.
|
FAF BAC | Hot Stocks09:01 EDT First American agrees to buy Bank of America's lien release business operations - First American Financial (FAF) announced the signing of an agreement to acquire Bank of America's (BAC) lien release business, which includes an agreement to provide these services to Bank of America going forward. The transaction is expected to close in the first quarter of 2018. Once the sale is complete, Bank of America's lien release business and its employees will become part of First American's Mortgage Solutions division, a leading provider of comprehensive solutions for residential lenders and servicers covering the entire loan spectrum.
|
VAC | Hot Stocks09:01 EDT Marriott Vacations raises quarterly dividend 14.2% to 40c from 35c per share - The dividend is payable on January 4, 2018 to shareholders of record as of December 21, 2017.
|
ULBI | Hot Stocks08:47 EDT Ultralife awarded $3.9M communications systems contract - Ultralife has been awarded a contract valued at approximately $3.9M to supply its Vehicle Amplifier-Adaptor to Thales Defense & Security, Inc., a global leader in the development, manufacture, and support of combat-proven, software-defined radio equipment, for the U.S. Army's Security Force Assistance Brigades, or SFABs, and other opportunities. SFABs are new brigades formed to advise and assist our partner nations in developing their local security force capability from the tactical to ministerial level. Initial shipments are expected to commence before the end of 2017 and continue during the first half of 2018.
|
NEOG | Hot Stocks08:45 EDT Neogen announces 4-for-3 stock split - Neogen announced that its Board of Directors has approved a four-for-three stock split. With the split, shareholders of record on Dec. 18, 2017, will receive one additional share of stock for each three shares held. The stock split will be effected in the form of new common stock being issued on Dec. 29, 2017, to shareholders of record as of the close of business on Dec. 18, 2017. As of today, Neogen has approximately 38,630,000 shares of common stock outstanding. After the split, the company will have approximately 51,500,000 shares of common stock outstanding. This is the company's fifth stock split. The most recent was a three-for-two split in October 2013.
|
GTHP | Hot Stocks08:45 EDT Guided Therapeutics signs preliminary license agreement with Turkish partner - Guided Therapeutics announced that has signed a preliminary license agreement with its Turkish distribution partner ITEM for the manufacture of patented single-patient-use Cervical Guides in Turkey. In return for the license and manufacturing rights for Cervical Guides in Turkey, GTHP will receive fees totaling $3M in 2018. In addition, ITEM will pay GTHP a royalty for each Cervical Guide made and sold exclusively in Turkey and ITEM will be obligated to purchase 600 LuViva Advanced Cervical Scans and produce 3 million Cervical Guides for the Turkish market over the next five years.
|
PFE | Hot Stocks08:33 EDT Pfizer: Talazoparib significantly extends PFS in Phase 3 EMBRACA trial - Pfizer announced that the Phase 3 EMBRACA trial in patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival in patients treated with talazoparib, compared to patients who received physician's choice standard of care chemotherapy. Median PFS was 8.6 months for those treated with chemotherapy. This represents a 46% reduction in the risk of disease progression. In addition, the proportion of patients achieving a complete or partial response in the talazoparib group was more than twice that of the control arm. Talazoparib is an investigational, oral, dual-mechanism poly ADP ribose polymerase inhibitor that is taken once daily. The data will be presented today as an oral presentation at the 2017 San Antonio Breast Cancer Symposium. The results of the EMBRACA trial also showed that the PFS benefit with talazoparib was consistent across prespecified subgroups, including hormone receptor status, prior chemotherapy, and history of central nervous system metastases. There also was a statistically significant delay in the time to clinically meaningful deterioration in global health status/quality of life with talazoparib versus chemotherapy, as measured by the EORTC QLQ-C30, a cancer-specific, patient-reported quality of life questionnaire.
|
ARNC | Hot Stocks08:31 EDT Arconic divests Latin American Extrusions business - Arconic announced the divestiture of its Latin America Extrusions business, which operates primarily in Brazil. The business is part of the Company's Transportation and Construction Solutions segment. Following customary regulatory and anti-trust reviews, the ownership of LAE will be transferred to a subsidiary of Hydro Extruded Solutions AS. The deal is expected to close in the first half of 2018. The divestiture is part of Arconic's continued drive to streamline its business portfolio, reduce complexity and further focus on its higher-margin products and continuous profitable growth. Under the terms of the agreement, Arconic will receive approximately $10M in cash for the LAE business, subject to working capital and other adjustments. As a result of the transaction, Arconic will recognize a restructuring-related charge representing the loss on sale of approximately $40M after-tax, or 8c per diluted share, in the fourth quarter of 2017, as referenced in the company's third quarter Form 10-Q filing. The charge primarily relates to the non-cash impairment of the net book value of the business. The charge is a special item and will not impact adjusted earnings per share.
|
B MTRN | Hot Stocks08:22 EDT Barnes Group names Materion executive chairman Richard Hipple to board - Barnes Group (B) announced that Richard J. Hipple has been elected to the company's Board of Directors, effective immediately. Richard J. Hipple is currently the Executive Chairman of Materion Corporation (MTRN). Hipple, has served as Executive Chairman since March 2017, and will be retiring from this position at the end of 2017. Previously, he served as Materion's Chairman and CEO from 2006 to 2017, and President and COO from 2005 to 2006.
|
AMZN | Hot Stocks08:06 EDT Amazon Music Unlimited expands to 28 more countries around the world - Amazon Music Unlimited, Amazon's full-catalog streaming service, announces its expansion into 28 additional countries, offering a catalog of more than 40 million songs and thousands of playlists and personalized stations, hand-curated by Amazon Music experts, to millions more listeners around the globe. New customers in these countries can now begin unlimited, ad-free streaming of new releases from chart-topping artists including J Balvin, Katy Perry, Luis Fonsi, Post Malone and many more on Amazon Music Unlimited within the Amazon Music app for iOS, Android, Mac, PC, Fire TV and on any Web browser. Also, Amazon Echo will begin to ship to these new countries, enabling customers who purchase devices the ability to experience Amazon Music Unlimited with the power and simplicity of natural voice controls in English, powered by Alexa, Amazon's cloud-based voice service.
|
SLNO | Hot Stocks08:06 EDT Soleno Therapeutics announces JV agreement wtih Capnia subsidiary - Soleno Therapeutics announced that it, and its wholly-owned subsidiary, Capnia, Inc., have entered into a Joint Venture, or JV, agreement with OptAsia Healthcare Limited, or OAHL, a Hong Kong-based healthcare firm, for the development and commercialization of Capnia's Sensalyze technology, which includes the CoSense End-Tidal Carbon Monoxide monitor that assists in the detection of excessive hemolysis in neonates, and other related products. Under the terms of the JV agreement, OAHL will invest up to $2.2M in tranches to purchase shares of our Capnia subsidiary and as a result of this investment, Capnia will no longer be a wholly-owned subsidiary of Soleno. Going forward, OAHL will be responsible for funding the operations of Capnia. In addition, OAHL has the option to buy the remaining shares of Capnia at a prespecified future time, and at a value based on revenue.
|
GIGM | Hot Stocks08:04 EDT GigaMedia CEO acquires 55,070 shares of company stock - GigaMedia announced that its CEO, Cheng-Ming Huang a.k.a. James Huang, has purchased a total of 55,070 shares of GigaMedia stock by Pacific Star Universal Group Ltd. at an average price of $2.9375 on December 6. The purchases were made during an open window period and in full compliance with all company and legal guidelines. Cheng-Ming Huang now holds a total of 292,678 shares.
|
MSGN | Hot Stocks08:02 EDT MSG Networks announces $150M stock repurchase program - MSG Networks announced that its board has authorized a stock repurchase program, under which the company may repurchase up to $150M of its outstanding Class A common stock.
|
TAC | Hot Stocks08:02 EDT TransAlta comments on provincial carbon credit regime - TransAlta responded favourably to details of the Government of Alberta's determination to permit carbon credits to be earned by existing wind and hydro generation in the Alberta fleet. On December 6, 2017, the Government of Alberta announced its intention to adopt a carbon credit regime that will fully recognize the value of carbon reductions from the generation of electricity from existing renewable assets. Under Alberta's output based allocation system for carbon emissions, TransAlta's existing wind and hydro facilities will receive credits for emissions below the performance standard of 0.37 tonnes of CO2 per MWh. Effective January 1, 2018, these credits can be used to offset up to 40%, escalating to 60% by 2022, of the carbon price obligations incurred by generation that exceeds the performance standard, which will be charged a price of $30 per tonne of CO2. The carbon credit regime will allow the Company to allocate the emissions benefits from its existing renewables generation in Alberta to offset the direct carbon costs of its thermal generation, including generation from its coal-to-gas converted units. "The recent announcement by the provincial government will more competitively position our existing renewable generation," said Dawn Farrell, President and CEO. "By treating existing renewable generation equally, we expect to eventually receive $30 million to $50 million annually in credits attributable to our existing renewable assets."
|
AEZS | Hot Stocks08:01 EDT Aeterna Zentaris announces departure of interim CFO - Aeterna Zentaris announced the departure of the company's Interim CFO, Jeffrey Whitnell, effective December 7. The company is currently reviewing its resource requirements with respect to its finance department and has commenced a search for Whitnell's replacement as principal financial officer.
|
STLY | Hot Stocks07:49 EDT Stanley Furniture announces CEO transition - Stanley Furniture announced that Glenn Prillaman, president and CEO, has resigned pursuant to a separation agreement entered into between the company and Prillaman in connection with the previously announced proposed sale of substantially all the company's assets. Matthew Smith has been elected Interim CEO. Smith is a managing director with The Finley Group, Inc., an advisory firm providing various services to corporations including interim management support. The Company's Board of Directors engaged the Finley Group in October 2017 to assist with a potential sale transaction and with working capital management. The company also announced that three sales representatives have been elected as Vice Presidents of the company. Josh Carter has been promoted to Vice President of Sales - Brick & Mortar, John Pigg has been promoted to Vice President of Sales - Interior Design, and Landon Smith has been promoted to Vice President of Sales - E-Commerce. The company also announced that Michael Haley and Justyn Putnam have informed the company that they plan to resign as directors. Putnam's resignation as a director is pursuant to the terms of a share purchase agreement under which the Talanta Fund, L.P. will sell its 740,896 shares of Stanley common stock to the Hale Partnership Fund, L.P. Mr. Putnam serves as investment manager of the general partner of the Talanta Fund, L.P. Steven Hale II is the sole manager of the investment manager for the Hale Partnership Fund, L.P. Putnam's resignation will be effective upon the closing of the share purchase. Haley's resignation will be effective concurrently with Mr. Putnam's resignation.
|
EACQ | Hot Stocks07:45 EDT Easterly Acquisition, JH Capital provide business, transaction updates - JH Capital Group Holdings and Easterly Acquisition announced business updates and an update to the anticipated timing to close the business combination announced on June 30, 2017. Since June 2017, JH Capital has seen a strengthening in capital deployment opportunities that provide strong rates of return. JH Capital's estimate for 2018E economic earnings has increased by approximately 12% from $50 million to $56 million since its June 30, 2017 projections. The company now anticipates outperforming its capital deployment estimate for 2018 by $10 million, expecting to deploy a total of $219 million for 2018. The company believes that if certain purchases had not been delayed due to the impact of hurricane season and if the business combination had closed as previously contemplated, providing immediate purchasing power, the company could have outperformed its targeted purchases for 2017 by approximately 26%. With the engagement of PricewaterhouseCoopers as its new auditor, JH Capital and PwC have undertaken a ground-up review of all of JH Capital's accounting policies and procedures, including clarification of certain accounting guidelines with the U.S. SEC. This review has resulted in two changes that will not affect future cash flow, but will materially impact GAAP revenue and earnings.
|
HXL | Hot Stocks07:33 EDT Hexcel to acquire A&D business of Oxford Performance Materials - Hexcel announced that it has entered into a definitive agreement to acquire the Aerospace & Defense, or A&D, business of Oxford Performance Materials, or OPM. OPM A&D produces qualified, high-performance thermoplastic, carbon fiber reinforced 3D printed parts for Commercial Aerospace and Space and Defense applications. The acquisition is subject to customary conditions and is expected to close later this month. The asset acquisition will include equipment, intellectual property and manufacturing process technology related to the A&D business operations in South Windsor, Connecticut. Other businesses of OPM are not included in the acquisition.
|
IPXL | Hot Stocks07:31 EDT Impax receives tentative FDA approval of generic version of Coreg CR capsules - Impax Laboratories announced it has received tentative U.S. FDA approval on its Abbreviated New Drug Application for a generic version of Coreg CR extended-release capsules, 10, 20, 40 and 80 mg. The company's ANDA is eligible for final approval upon the expiration of marketing exclusivity on May 7, 2018. Carvedilol phosphate extended-release capsules had U.S. brand sales of approximately $206M, according to IMS Health for the 12 months ending October 2017.
|
ITG | Hot Stocks07:03 EDT ITG reports November U.S. trading volume 2.9B shares - ITG announced that November U.S. trading volume was 2.9B shares and average daily volume was 137M shares, compared to 2.8B shares and ADV of 126M shares in October 2017 and 3.3B shares and ADV of 159M shares in November 2016. There were 21 trading days in both November 2017 and November 2016 and 22 trading days in October 2017.
|
EVH | Hot Stocks07:02 EDT Evolent Health, Premier Health terminate stock purchase agreement - Evolent Healt announced that Evolent and Premier Health have terminated the stock purchase agreement whereby Evolent was to purchase Premier Health Plan. The two parties were unable to reach terms on the related party agreements. Evolent will continue to provide services and support in accordance with the existing administrative agreement for the employee self-insured, Medicare Advantage and commercial large group health plans that Premier will continue to own and operate. Premier and Evolent look forward to continuing to collaborate on value-based services covered by their present agreement as Premier continues to explore strategic options for its health plan business.
|
KO | Hot Stocks06:59 EDT Coca-Cola: Irial Finan to retire as EVP, President, Bottling Investments Group - The Coca-Cola Company announced that Irial Finan, a 36-year veteran of the Coca-Cola system, plans to retire from his post as Executive Vice President and President of Bottling Investments Group, or BIG. Calin Dragan, who currently serves as Regional Director for BIG's ASEAN and Middle East bottlers, will be promoted to lead BIG. Finan, who reports to President and CEO James Quincey, will retire March 31, 2018. He will step down from his current role on Dec. 31 and will remain with the company as executive advisor until his retirement. Dragan, who begins his new role as President of BIG on Jan. 1, 2018, is based in Singapore and will report to John Murphy, President of Coca-Cola's Asia Pacific Group. Dragan will oversee BIG operations globally. BIG, which will continue to play a significant role in contributing to Coca-Cola's overall growth, is now largely concentrated in the Asia Pacific region. The company continues to work toward refranchising Coca-Cola Beverages Africa, which is part of BIG. Dragan has 24 years of experience in the Coca-Cola system, including a succession of bottling leadership roles in Asia Pacific and Europe. Prior to his current role, he served as Representative Director and acting Chairman, President and CEO for Coca-Cola East Japan.
|
STDY | Hot Stocks06:57 EDT SteadyMed announces FDA agreed pathway to Trevyent NDA resubmission - SteadyMed announced it has received final minutes from the U.S. FDA on the work necessary to resubmit its New Drug Application for Trevyent for the treatment of Pulmonary Arterial Hypertension. The minutes followed a positive and collaborative Type A meeting with the FDA on November 1, 2017. The FDA is not requiring SteadyMed to conduct any clinical trials to prove the safety or efficacy of Trevyent and has agreed that a repeat of in vitro Design Verification testing on the final to-be-marketed Trevyent product, supported by pharmacokinetic modelling and Process Validation, should be adequate for the resubmission and acceptance of the 505(b) New Drug Application. The purpose of in vitro DV testing is to confirm that Trevyent performance meets its design specifications. The testing is designed to confirm product performance under various conditions on the final, to-be-marketed, Trevyent product. SteadyMed has begun the pre-DV activities, which precede the DV testing, with Trevyent performance data being available around mid 2018. SteadyMed expects both NDA submission and acceptance to occur before the end of 2018. SteadyMed ended Q3 2017 with a strong cash position of $37.4M, providing more than sufficient capital to fund operations through the NDA resubmission and acceptance.
|
CDXC | Hot Stocks06:32 EDT ChromaDex: Published research shows nicotinamide riboside improves memory - ChromaDex announced that in research published in the journal Nature, Dr. Johan Auwerx showed that Alzheimer's disease mice treated with nicotinamide riboside had lower levels of amyloid deposits, improved mitochondrial energy production and improved memory.
|
FENG | Hot Stocks06:07 EDT Phoenix New Media announces new trademark license agreement with Phoenix TV - Phoenix New Media announced that it has, through certain of its affiliated consolidated entities, entered into new trademark license agreements with a subsidiary of its parent company, Phoenix Satellite Television Holdings, to replace previous trademark license agreements between the parties. Under the New Agreements, Phoenix TV agreed to continue to license to the Licensees certain trademarks containing the double-phoenix logo and the Chinese or English words of "Phoenix New Media" or "ifeng" for an initial term of three years, while the Licensees are not allowed to use the double-phoenix logo on a stand-alone basis. The Licensees are also granted a one-year license to continue to use the current marks of the company's two mobile applications which contain the Chinese words of "Phoenix News" and "Phoenix Video" which will be automatically renewed upon its expiration unless Phoenix TV raises any objection. The annual license fee payable to Phoenix TV by each of the Licensees will be the greater of 2% of the Licensee's annual revenue or $100,000, while the annual fee under the Previous Agreements was $10,000.
|
UNVR | Hot Stocks06:06 EDT Univar acquires Kemetyl Industrial Chemicals - Univar announced that its wholly owned subsidiaries Univar AB in Sweden and Univar AS in Norway have reached an agreement to acquire Kemetyl Industrial Chemicals, a division of the Kemetyl Group. The company generates approximately $30M in annual sales. The acquisition is expected to close in early 2018.
|
TEL | Hot Stocks06:04 EDT TE Connectivity approves dividend increase recommendation to 44c per share - TE Connectivity also approved a recommendation to increase the company's quarterly dividend from 40c to 44c per share, for the four fiscal quarters starting in April 2018, the beginning of the third fiscal quarter. The recommendation would raise the company's dividend from the annual rate of $1.60 per share to $1.76 per share, and will be presented for shareholder approval at the company's Annual General Meeting of Shareholders on March 14, 2018.
|
SYBX | Hot Stocks06:02 EDT Synlogic, Ginkgo Bioworks announce collaboration - Ginkgo Bioworks and Synlogic announced a collaboration to discover new living medicines to treat neurological and liver disorders. Synthetic Biotic medicines are living medicines in which engineered probiotics are designed to perform critical metabolic conversions in the gut that can replace physiological activity missing or damaged in patients. Together, Synlogic and Ginkgo aim to transform the discovery and design of living medicines. Ginkgo's automated foundry and expertise in high-throughput organism screening and design, combined with Synlogic's insights and expertise in discovery, translational and clinical development of Synthetic Biotic medicines will enhance Synlogic's powerful drug discovery engine, enabling iteration through thousands of drug leads with great speed and precision. Synlogic's core expertise in building Synthetic Biotic medicines for clinically-relevant potency, quantitative pharmacology, dose response, and reproducible manufacturing will further accelerate the development of novel gut-based therapeutics. This collaboration is the first step toward an anticipated broad effort to generate a portfolio of transformational living medicine drug leads. The focus of this collaboration will be combining optimization capabilities, establishing the working model behind the joint discovery engine, and generating drug leads. The parties expect to further collaborate to explore how their technologies can be used to treat a broad range of neurological and liver conditions. The companies will jointly seek strategic partners for portfolio expansion, clinical development, and commercialization in these disease areas. Financial terms of the collaboration are not disclosed.
|
HMC | Hot Stocks06:02 EDT Honda, SenseTime sign R&D contract for self-driving car technology - As part of its efforts to establish automated driving technologies to realize a collision-free society, Honda R&D Co., Ltd., the R&D subsidiary of Honda Motor Co., Ltd., today announced that it has signed a 5-year joint research and development contract with SenseTime Group Limited, a China-based IT company with strengths in the area of artificial intelligence technologies. In this joint research and development, combining SenseTime's moving object recognition technologies with Honda's AI algorithms for scene understanding, risk prediction and action planning, the two companies will develop highly-sophisticated automated driving technologies which will enable complex automated driving in urban areas. Moreover, this joint research and development will not be limited to automated driving, as the two companies plan to expand the joint activities into the area of robotics.
|
TEL | Hot Stocks06:01 EDT TE Connectivity announces additional $1.5B share repurchase - TE Connectivity announced that its board has authorized an increase in its share repurchase program by an additional $1.5B.
|
TEL | Hot Stocks06:01 EDT TE Connectivity announces additional $1.5B share repurchase, dividend increase
|
QCOM BIDU | Hot Stocks05:57 EDT Qualcomm, Baidu form AI partnership to optimize DuerOS for Snapdragon - Qualcomm Technologies, Inc., a subsidiary of Qualcomm (QCOM), and Baidu (BIDU) yesterday announced that the companies will work together to optimize Baidu's DuerOS conversational artificial intelligence system for smartphones on the Qualcomm Snapdragon Mobile Platform, including the upcoming Snapdragon 845 Mobile Platform. This strategic collaboration will utilize both parties' experience and expertise in AI to optimize DuerOS with the Qualcomm Aqstic hardware and software, to support a complete AI voice and smart assistant solution for global smartphone and Internet of Things devices. This collaboration aims to support the availability of optimized DuerOS reference application for upcoming software releases on Snapdragon mobile platforms giving OEMs the ability to deliver AI voice solutions on their devices with improved user experience and faster time-to-market.
|
TSM | Hot Stocks05:45 EDT TSMC reports November revenue NT$93.15B vs. NT$93.03B last year
|
HIMX | Hot Stocks05:34 EDT Himax 'strongly' denies Citron Research allegations of fraud - Himax Technologies responded to a tweet published by Citron Research, an online stock commentary blog, dated December 6. The company reaffirms its commitment to transparent and reliable shareholder communication, and its adherence to the highest standards of corporate governance. Himax cautions investors that Citron Research has never made any contacts with the company and that the tweet did not contain any input from the company. Himax categorically denies any and all allegations of fraud. "Himax welcomes an open dialogue with any and all shareholders," said Jordan Wu, President and CEO of Himax. "The accusations made by Citron Research are baseless and both the management team and board of directors strongly disagree with their comments."
|
NVS | Hot Stocks05:32 EDT Sandoz announces new proposed biosimilar pegfilgrastim Phase I data - Sandoz, a division of Novarti, announced data demonstrating the pharmacokinetics, or PK, pharmacodynamics, or PD, safety and immunogenicity of proposed biosimilar pegfilgrastim as compared to the reference biologic, Neulasta. The Phase I study, conducted in healthy volunteers, confirmed that Sandoz biosimilar pegfilgrastim matches the reference biologic in terms of PK, PD, safety and immunogenicity profiles. The data were presented during the 2017 San Antonio Breast Cancer Symposium.
|
EXPO | Hot Stocks05:28 EDT Exponent announces 2018 succession plan, names Dr. Catherine Ford Corrigan CEO - Exponen announced that its board intends to appoint Exponent's President, Dr. Catherine Ford Corrigan as its CEO and President at its board meeting following the annual shareholder meeting on May 31, 2018. Exponent's current CEO, Dr. Paul Johnston is expected to become Chairman of the board at that time. In addition, to assist in the transition, he will continue in an executive role on a half-time basis for twelve months. Exponent's current Chairman of the board, Michael Gaulke, is planning to retire and will not stand for re-election in 2018. Additionally, Exponent's board intends to appoint Dr. John Shoven as Lead Independent Director in May. Dr. Corrigan joined Exponent 21 years ago and has assumed increasingly responsible positions over time.
|
EXPO | Hot Stocks05:27 EDT Exponent announces 2018 succession plan, names Dr. Catherine Ford Corrigan CEO - Exponen announced that its board intends to appoint Exponent's President, Dr. Catherine Ford Corrigan as its CEO and President at its board meeting following the annual shareholder meeting on May 31, 2018. Exponent's current CEO, Dr. Paul Johnston is expected to become Chairman of the board at that time. In addition, to assist in the transition, he will continue in an executive role on a half-time basis for twelve months. Exponent's current Chairman of the board, Michael Gaulke, is planning to retire and will not stand for re-election in 2018. Additionally, Exponent's board intends to appoint Dr. John Shoven as Lead Independent Director in May. Dr. Corrigan joined Exponent 21 years ago and has assumed increasingly responsible positions over time.
|